Lv3
394 积分 2025-06-09 加入
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma
26天前
已完结
Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study
1个月前
已完结
Anbenitamab is a new second-line option in G/GEJ adenocarcinoma
1个月前
已完结
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study
1个月前
已完结
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study
1个月前
已完结
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
2个月前
已完结
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
2个月前
已完结
Tulisokibart shows promise for Crohn's disease
2个月前
已关闭
TL1A: A model for a precision medicine approach in the treatment of Crohn’s disease and ulcerative colitis
2个月前
已完结
Intestinal Fibrosis in Crohn’s Disease: Pathophysiology, Diagnosis, and New Therapeutic Targets
2个月前
已完结
皖公网安备34019202002308
